Clinical trial
A Phase Ib/II Open-Label Study of APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma and Immunoglobin Light Chain Amyloidosis
NCT04942067 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib/II Open-Label Study of APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma and Immunoglobin Light Chain Amyloidosis
- Lead sponsor
- Ascentage Pharma Group Inc.
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- December 23, 2021
- Completion date
- December 1, 2024
- Enrollment
- 108 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.